Citations

Clear

16281 citation(s) found for "Li, David".

Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma
Abdallah, Nadine , Marar, Rosalyn, Yee, Claire , Bodily, Anna, Truman, Mia, Wildes, Tanya, Weivoda, Megan , Aug, Sarah, Smith, Byron, Kapoor, Prashant , Hayman, Suzanne R. , Dingli, David, Gonsalves, Wilson I, Zanwar, Saurabh , Kourelis, Taxiarchis , Warsame, Rahma , Lin, Yi, Rajkumar, S Vincent, Kumar, Shaji , Yee, Claire , Menser, Terri , Weivoda, Megan , Buadi, Francis K , Dispenzieri, Angela , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Kourelis, Taxiarchis , Gertz, Morie A , Warsame, Rahma , Dueck, A. C. , Kumar, Shaji K , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Gertz, Morie A. , Rajkumar, S. Vincent , Dueck, Amylou C.

Mayo Clinic

Blood Advances | July 28, 2026 | Volume: 10 | Issue: 20 | Pages: 6957-6967

10.1182/bloodadvances.2026020579 | PMID 42508993 Get It

Abstract Frailty influences treatment outcomes in older patients with multiple myeloma (MM), yet existing frailty tools capture limited geriatric domains and are incompletely studied in the context of contemporary therapies. We prospectively evaluated patient-reported comprehensive geriatric assessment (CGA) domains and their associations with treatment toxicity and patient-reported outcomes (PRO) in older adults with MM. Patients aged ≥60 years with newly diagnosed or relapsed/refractory MM initiating a new therapy completed electronic CGA and PRO questionnaires at baseline and 4 months. Outcomes included clinician- and patient-reported treatment toxicity, treatment adaptations, health care use, and health-related quality of life (HRQOL). A cumulative deficit frailty index (FI) was derived from CGA and HRQOL domains. Among 90 patients (mean age, 72 years), geriatric impairments were common, particularly physical function domains. High-grade nonhematologic toxicities were significantly associated with older age, comorbidities, patient-reported functional limitations, and anxiety. Toxicity rates on the PRO version of the Common Terminology Criteria for Adverse Events (CTCAE) were higher than on CTCAE, highlighting a discordance between physician- and patient-reported treatment toxicity. Frailty was present in 22% and associated with worse baseline HRQOL and increased high-grade nonhematologic toxicity but not treatment adaptations or health care use. Average CGA and HRQOL scores remained stable over 4 months, although individual trajectories varied. Patient-reported geriatric impairments are prevalent in older adults with MM and strongly associated with nonhematologic toxicities even in the contemporary treatment era. Physician-reported CTCAE may not fully reflect patients' symptom burden. Heterogeneity in individual geriatric trajectories during treatment emphasize the need for longitudinal assessment. This study was registered at www.clinicaltrials.gov as NCT05918185.
Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma
Bolarinwa, Abiola , Zanwar, Saurabh , Abdallah, Nadine , Nagaraj, Madhu , Seth, Sukriti, Buadi, Francis K. , Hayman, Suzanne R. , Gertz, Morie A. , Muchtar, Eli , Kapoor, Prashant , Gonsalves, Wilson I, Kourelis, Taxiarchis , Dingli, David, Warsame, Rahma , Lin, Yi, Hwa, Y., Rogers, Michelle Genevieve, Hobbs, Miriam A, Fonder, Amie , Jevremovic, Dragan, Rajkumar, S Vincent, Kumar, Shaji , Zanwar, Saurabh S , Dispenzieri, Angela , Muchtar, E , Kourelis, Taxiarchis , Warsame, Rahma , Leung, Nelson , Cook, Joselle M , Binder, Moritz , Hwa, Yi Lisa, Fonder, Amie , Kumar, Shaji K , Gertz, Morie A , Buadi, Francis K , Bolarinwa, Abiola B , Dispenzieri, Angela , Gonsalves, Wilson I. , Dingli, David , Leung, Nelson , Cook, Joselle , Binder, Moritz , Hobbs, Miriam, Jevremović, Dragan , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | July 28, 2026 | Volume: 10 | Issue: 19 | Pages: 6694-6702

10.1182/bloodadvances.2026020294 | PMID 42508994 Get It

Abstract Measurable residual disease (MRD) is a powerful prognostic tool in multiple myeloma, but predictors of achieving MRD negativity after autologous stem cell transplantation (ASCT) are not well defined. We studied 814 patients who achieved at least a very good partial response after ASCT between January 2016 and January 2023 and underwent MRD assessment by next-generation flow cytometry. Overall, 387 (48%) achieved MRD negativity after ASCT. The presence of t(11;14) (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.4–3.2; P< .01) and pretransplant response less than complete remission (OR, 2.1; 95% CI, 1.2-3.7; P< .01) independently predicted MRD positivity. Patients who were MRD positive had inferior progression-free survival (PFS; hazard ratio [HR], 1.99; 95% CI, 1.53-2.58; P< .001) and overall survival (HR, 1.62; 95% CI, 1.10-2.28; P = .009). Despite lower MRD-negative rate, 5-year PFS was similar among t(11;14) MRD positive (58%) and patients who were MRD negative (63%; P = .12). In patients who were MRD negative, the 5-year PFS was 73% in those without ≥2 HRCA compared with 55% in those with ≥2 HRCA (HR 1.9, 95% CI 1.2–3.3; P = .01). In the MRD-positive cohort, 5-year PFS was 53% in patients without ≥2 HRCA vs 17% in those with ≥2 HRCA (HR, 2.4; 95% CI, 1.6-3.6; P< .01). In addition, higher residual clonal plasma cell burden within MRD-positive disease was associated with inferior PFS (HR, 2.4; 95% CI, 1.2-6.9; P = .002). This study highlights that the presence of t(11;14) independently predicts MRD positivity after ASCT, although it does not significantly affect prognosis in this subgroup.
Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study
Zarif, Talal El, Alaiwi, Sarah Abou, Gariazzo, Eleonora, Santo, Valentina, Garbo, Edoardo , Aldea, Mihaela, Pannu, Sagal, Semaan, Karl , Chehab, Omar , Hoballah, Malak, Y, Gao , Meyers, Daniel, Stukalin, Igor , Li, MT, Jones, Nicholas, Shapira, Ronnie, Vasbinder, Alexi, Hayek, Salim S. , Eid, Marc , Freeman, Dory, Parikh, Kaushal, Desai, Aakash, Cd, Smith, El-Am, Edward, Foderaro, Simone , Baena-, Javier, Cortellini, Alessio, Pinato, David J, Korolewicz, James , Kim, Chul , Sackstein, Paul, Denu, Ryan A, Abdel-wahab, Noha, Neilan, Tomas G. , Lima, Joao A C, Florez, Narjust, Janne, Pasi, Pecci, Federica , Choueiri, Toni K, Kwan, Jennifer M. , Naqash, Abdul Rafeh , Desai, Aakash , El Zarif, Talal , Garbo, Edoardo , Semaan, Karl , Grynberg, Shirly , Bou Farhat, Elias , Eid, Marc , Saad, Eddy , Desai, Aakash P , Kim, Chul , Jänne, Pasi A , Naqash, Abdul Rafeh , Hayek, Salim , Alaiwi, Sarah Abou , Nassar, Amin H. , Gariazzo, Eleonora , Santo, Valentina , Aldea, Mihaela , Paoloni, Francesco , Chehab, Omar , Navani, Vishal , Meyers, Daniel E. , Mittra, Arjun , Grynberg, Shirly , Vasbinder, Alexi L. , Farhat, Elias Bou , Saad, Eddy , Freeman, Dory , El‐Am, Edward , Nana, Frank Aboubakar , Baena, Javier, Herrera, Mercedes, Cortellini, Alessio , Pinato, David J. , Sackstein, Paul , Denu, Ryan , Macaron, Walid , Abdel‐Wahab, Noha , Lima, João A.C. , Florez, Narjust , Jänne, Pasi A. , Ricciuti, Biagio , Choueiri, Toni K.

Mayo Clinic

The Oncologist | July 25, 2026 | Volume: 31 | Issue: 9 | Pages: No page available

10.1093/oncolo/oyag277 | PMID 42500986 Get It

Abstract Background There is limited data on immune checkpoint inhibitor (ICI) use in patients with non-small cell lung cancer (NSCLC) and known pericardial effusions. Methods This international multi-center observational retrospective study included patients with advanced NSCLC with or without pericardial effusions receiving ICIs. Immune-related adverse events (irAEs) were graded per CTCAE v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Cox proportional hazards multivariable models assessed the association between survival outcomes and clinicopathologic variables, and an inverse probability of treatment weighting (IPTW) model compared outcomes between the two groups. Results A total of 1248 patients with advanced NSCLC treated with ICIs across 13 institutions were included. Of these, 85 patients (6.8%) had pre-existing pericardial effusions. Compared to controls, patients with pericardial effusions were younger (median age 63 vs 67 years, P = .007), diagnosed more frequently with PD-L1 positive tumors (96% vs 76%, P < .001), and had a higher median number of baseline metastatic sites (3 vs 1, P < .001). IrAEs were similar between both groups (42% vs 38%), and no cardiac irAEs occurred in patients with pericardial effusions. PFS (median 5.6 vs 4.6 months, P = .3) and OS (median 10.2 vs 14.7 months, P = .50) were not statistically different between patients with pericardial effusions and the controls, respectively. In both multivariable and IPTW models, pericardial effusions were not associated with PFS or OS. Conclusions Among patients with NSCLC and pre-existing pericardial effusions, ICIs demonstrate meaningful clinical benefit similar to those without effusions, with no new cardiac or severe toxicities.
Reporting and Analysis of Sociodemographic Characteristics in High-impact Perioperative Medicine Studies: A Scoping Review
Kraus, Molly, Noss, Bryant, Burton, Brittany N., Maloney, Jillian, Warner, David O., Wang, Z, Mariano, Edward R., Boulware, Angel , Milam, Adam J. , Milam, Adam J , Kraus, Molly B., Burton, Brittany N. , Maloney, Jillian , Yu, Soojie , Warner, David O. , Mariano, Edward R.

Mayo Clinic

Anesthesiology Open | July 24, 2026 | Volume: 1 | Issue: 2 | Pages: e0025

10.1097/ao9.0000000000000025 Get It

First-pass aspiration versus stent retriever thrombectomy: machine learning study of treatment effect heterogeneity
Chen, Huanwen , Isidor, Julio , Schirmer, Clemens, Ernst, Marielle , Rai, Ansaar, Jabbour, Pascal , Abecassis, Isaac Josh , Grossberg, Jonathan A , Alawieh, Ali, Khanna, Omaditya, Starke, Robert M, Psychogios, Marios-Nikos, Siddiqui, Fazeel, Samaniego, E, Goyal, Nitin, Ezzeldin, Mohamad , Dye, Justin, Alcedo, Rodolfo, Cerejo, Russell , Luther, Evan, Romano, Daniele G, Tanweer, Omar, Mascitelli, Justin, Cuellar, Hugo H, Chalouhi, Nohra , Limaye, Kaustubh, Kellogg, Ryan, Brinjikji, Waleed, Chowdhry, Shakeel , Spiotta, Alejandro M , Kan, Peter , Jabbour, Pascal , Abecassis, Isaac Josh , Grossberg, Jonathan A , Navia, Pedro , Ezzeldin, Mohamad , Alaraj, Ali , Yoshimura, Shinichi , Fiorella, David , Fragata, Isabel , Mokin, Maxim , Matouk, Charles , Chowdhry, Shakeel A , Altschul, David J , Ogilvy, Christopher S , Levitt, Michael R , Grandhi, Ramesh , Spiotta, Alejandro M , Kan, Peter , Kim, Jae‐Joong , Rai, Ansaar , Jabbour, Pascal , Navía, Pedro , Starke, Robert M. , Psychogios, Marios‐Nikos , Goyal, Nitin , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi , Almallouhi, Eyad , Fiorella, David , Romano, Daniele Giuseppe , Tanweer, Omar , Fragata, Isabel , Mascitelli, Justin R , Limaye, Kaustubh , Matouk, Charles , Kellogg, Ryan Thomson , Brinjikji, Waleed , Altschul, David , Ogilvy, Christopher S. , Levitt, Michael R. , Grandhi, Ramesh , Chen, Huanwen

Mayo Clinic

Journal of NeuroInterventional Surgery | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: jnis-2026-025615

10.1136/jnis-2026-025615 | PMID 42498630 Get It

Background Randomized trials have shown equivocal outcomes between a direct aspiration as first-pass technique (ADAPT) and stent retriever (SR) stroke thrombectomy, yet whether specific patient subgroups benefit differentially from one technique over the other remains unknown. Methods In this retrospective multicenter cohort study, patients with large vessel occlusion were included, and those who underwent ADAPT versus SR first-pass thrombectomy (either as standalone or combined with aspiration) were compared. The primary outcome was a composite of first-pass effect (FPE, modified Thrombolysis In Cerebral Infarction (mTICI) 2c or better with one attempt) with no symptomatic intracranial hemorrhage (sICH). A causal forest model was used to estimate the conditional average treatment effect (CATE) for each patient, with larger CATEs indicating that ADAPT is expected to be more advantageous. Patients were stratified by CATEs, and outcomes were compared between treatment groups. Results Among 6700 included patients, ADAPT (n=3695, 55%) was associated with a higher rate of FPE with no sICH (39.9% vs 26.9%; adjusted OR (aOR) 2.07, 95% CI 1.77 to 2.41, P<0.001). The causal forest identified significant treatment effect heterogeneity (interaction P<0.001), where ADAPT was more advantageous in more recent years and among patients with M1 occlusions presenting in earlier time windows. Low-CATE patients showed no statistically significant difference between techniques (aOR 0.91, 95% CI 0.57 to 1.45, P=0.70), while medium- and high-CATE patients demonstrated progressively larger ADAPT advantages (aOR 2.06, 95% CI 1.67 to 2.55, and aOR 2.99, 95% CI 2.24 to 3.98, respectively, both P<0.001). Conclusions ADAPT may be superior to SR for a majority of patients, particularly in recent years, and among patients with M1 occlusions presenting in earlier time windows.
Reply: Interpreting early default mode network dysfunction across the Alzheimer’s disease Spectrum
Jones, David T. , Corriveau‐Lecavalier, Nick , Jones, David T , Corriveau-Lecavalier, Nick

Mayo Clinic

Brain | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag254 | PMID 42500978 Get It

Symmetrical drug-related intertriginous and flexural exanthema: Insights from FAERS Database
Le, Duc V, Doan, Nhi H. , Tran, Hue T T, Nguyen, Vinh T H, Wetter, David A. , Nguyen, Giang H, Tran, Hue T.T. , Nguyen, Giang Huong

Mayo Clinic

Clinical and Experimental Dermatology | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ced/llag308 | PMID 42500923 Get It

Overall, our findings expand current understanding of SDRIFE by highlighting both well-recognized and underappreciated medication classes, underscoring the importance of ongoing pharmacovigilance.
Effectiveness of opportunistic bilateral salpingectomy in preventing epithelial ovarian cancer: a population-based study
Bahrami, Foruzan , McLeod, Julianne, Pearce, Celeste Leigh, Kushi, Lawrence H, Garcia, Christine, McAlpine, Jessica N, Gamez, Jamie N Bakkum, Tischer, Kristin M, Huntsman, David, Hanley, Gillian E, McAlpine, Jessica N. , Hanley, Gillian E. , Tischer, Kristin M. , Bakkum Gamez, Jamie N, McAlpine, Jessica N , Tischer, Kristin M. , Pearce, Celeste Leigh, Kushi, Lawrence H. , Garcia, Christine , Yong, Paul J. , Vera, Mary A. De , Gamez, Jamie N Bakkum

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag251 | PMID 42528271 Get It

Abstract Background Opportunistic bilateral salpingectomy (OBS), the removal of fallopian tubes during hysterectomy or instead of tubal ligation, is recommended to reduce ovarian cancer risk. However, data on the effectiveness of prophylactic OBS is limited. Methods This population-based retrospective cohort included individuals aged 18–80 in Ontario, Canada, who underwent OBS or comparator surgeries (hysterectomy with ovarian and tubal conservation or tubal ligation) from 2011 to 2023. Individuals with gynecologic cancer before or within six months of surgery were excluded. Hazard ratios and 95% confidence intervals were estimated using Cox proportional hazards regression. Sensitivity analyses varied the time between surgery and cancer diagnosis to account for pre-existing serous tubal intraepithelial carcinomas. Results Among 196,839 individuals, 57,941 underwent OBS and 138,898 underwent comparator surgeries. 142 epithelial ovarian cancers were diagnosed (19 in the OBS group and 123 in the comparator surgery group). OBS was associated with reduced risk of any ovarian carcinoma, with an adjusted hazard ratio (aHR) of 0.60 (95% CI, 0.36 to 0.98). For serous ovarian carcinoma (high- and low-grade combined due to missing grade data), the aHR was 0.47 (95% CI, 0.22 to 0.99). Sensitivity analyses with 12- and 18-month intervals showed aHRs of 0.59 (95% CI, 0.35 to 0.99) and 0.60 (95% CI, 0.35 to 1.01) for all ovarian carcinomas, and 0.49 (95% CI, 0.23 to 1.01) and 0.47 (95% CI, 0.22 to 0.99) for serous ovarian carcinoma, respectively. Conclusions OBS was associated with reduced risk of ovarian carcinoma, supporting its role as a primary prevention strategy.
Bridging Conservative Management With Injectable Orthobiologic Therapies: Proceedings of the International Consensus Meetings on Cartilage Repair of the Ankle
Tham, Alexander, Rubin, Jared, Butler, James J., Gauthier, Paloma , Kennedy, John G. , Adams, Samuel B., Andrews, Carol L., Batista, Jorge , Baur, Onno L., Bayer, Stephen, Becher, Christoph, Berlet, Gregory C. , Boakye, Lorraine AT, Buda, R, Calder, James D. F., Dahmen, Jari , D’Hooghe, Pieter, DiGiovanni, Christopher W., Ehlers, M. , Ferkel, Richard D. , Ferkel, Eric, Ferrao, Paulo N. F., Giza, Eric , Gianakos, Arianna L., Glazebrook, Mark, Gomaa, Mohamed, Görtz, Simon, Haleem, Amgad M. , Hamid, Kamran S. , Hangody, László, Haverkamp, Daniel, Hertel, Jay, Hintermann, Beat, Hogan, MaCalus V., Hunt, Kenneth J., Hurley, Eoghan T., Karlsson, Jon, Kearns, Stephen R. , Kerkhoffs, Gino M. M. J., Kim, Hak Jun , Kong, Siu Wah, Krebsbach, Sebastian, Labib, Sameh A. , Lambers, Kaj T. A. , Lee, Jin Woo, Lee, Keun Bae, Ling, Jeffrey S., Longo, Umile Giuseppe, Marangon, Alberto, McCollum, G, McCullough, Kirk, Mittwede, Peter N. , Murawski, Christopher D. , Nicolescu, Raluca, Niemeyer, Philipp, Nunley, James A., O'Malley, Martin, Ortiz, Cristian, Osei-Hwedieh, David O. , Paul, Jochen , Pearce, Christopher J., Pereira, Hélder , Phadke, Rohan , Prado, Marcelo P. , Raikin, Steven M., Reilingh, Mikel L., Robert, Guillaume , Lc, Schon, Simpson, Helene, Smyth, Niall A. , Sofka, Carolyn M., Spennacchio, Pietro, Stone, James W., Takao, M, Tanaka, Yasuhito, Thermann, Hajo, Thordarson, David B. , Rs, Tuan, Valderrabano, Victor, Bergen, Christian J. A. van, Dijk, Pim A. D van, Dijk, Niek van, Vannini, Francesca, Vaseenon, Tanawat , Volesky, Monika , Walls, Raymond C., Walther, Markus, Wiewiorski, Martin, Xu, Xiangyang, Yasui, Youichi , Yinghui, Hua, Yoshimura, Ichiro, Younger, Alastair , Zdanowicz, Urszala, Zhang, Zijun, Adams, Samuel B. , Clanton, Thomas O , Dahmen, Jari , Ehlers, Mallory , Hannon, Charles P , Labib, Sameh A , Popchak, Adam , Robert, Guillaume , Smyth, Niall A , Tham, Alexander , Rubin, J Peter , Butler, James J., Angthong, Chayanin , Becher, Christoph, Boakye, Lorraine A. T. , Buda, Roberto , Calder, James D. F. , Canata, Gian Luigi , Carreira, Dominic S. , Dahmen, Jari , d’Hooghe, Pieter P. R. N. , DiGiovanni, Christopher William , Dombrowski, Malcolm E. , Ferkel, Eric I. , Ferrao, Paulo N. F. , Gianakos, Arianna L. , Glazebrook, Mark Anthony , Gomaa, Mohamed, Hannon, Charles P. , Haverkamp, Daniël , Hintermann, Beat , Hogan, MaCalus Vinson , Hunt, Kenneth John , Hurley, Eoghan T. , Karlsson, Jon, Kerkhoffs, Gino M. M. J. , Krebsbach, Sebastian , Lee, Jin Woo , Longo, Umile Giuseppe , Mitchell, Adam W. , Nehrer, Stefan , Niemeyer, Philipp , Nunley, James A. , O’Malley, Martin , Pearce, Christopher Jon , Pereira, Hélder , Raikin, Steven M. , Rothrauff, Benjamin B. , Schon, Lew Charles , Spennacchio, Pietro , Sullivan, Martin, Tanaka, Yasuhito , Valderrábano, Víctor , Dijk, Pim A. D. van , Vannini, Francesca , Walther, Markus , Wiewiorski, Martin J., Xu, Xiangyang , Yoshimura, Ichiro , Zhang, Zijun

Mayo Clinic

Foot & Ankle Specialist | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19386400261456925 | PMID 42495946 Get It

Background The management of osteochondral lesions of the talus (OLT) is challenging, with 2 main options being conservative and surgical management. Orthobiologic therapies come to bridge the gap between these 2 options; however, inconsistencies in indication, composition, and heterogeneous evidence limit clinical decision-making. To address these challenges, 3 International Congress Meetings on Cartilage Repair of the Ankle were convened in Pittsburgh, USA (2017), Dublin, Ireland (2019), and New York, USA (2025) to establish agreement on the role of conservative management and injectable orthobiologic strategies in the treatment of OLT. Methods Seventy-five multidisciplinary experts from over 25 countries and 1 territory participated in a structured Delphi-based consensus process. Blinded surveys, structured questionnaires, and in-person discussions were used to develop and refine statements, supported by literature review and graded evidence (A1–E). Consensus strength was defined as consensus (51%-74%), strong consensus (75%-99%), or unanimous (100%) Results In total, 29 consensus statements were achieved across the 3 meetings. Strong agreement was reached regarding indications and expected outcomes of conservative management, including the role of immobilization and appropriate timing for surgical intervention. Orthobiologic injections, including platelet-rich plasma, concentrated bone marrow aspirate, and hyaluronic acid, were considered appropriate in select patients with persistent symptoms, although no superiority was demonstrated among formulations, preparation methods, or injection strategies. When used as adjuncts to surgical procedures, orthobiologics may improve radiological outcomes, with limited evidence for improvement in clinical outcomes. Technical considerations, including preferred harvest sites and a lack of standardized preparation protocols, were identified, along with key principles for patient counseling Conclusion These international consensus statements establish a standardized framework for the conservative management and use of injectable orthobiologic therapies in OLT. By clarifying indications, technical considerations, and current limitations, this work aims to improve consistency in clinical practice, guide treatment decision-making, and inform future research.
Characteristics of Gender-Diverse Patients With Breast Cancer
Cortina, Chandler S., Brazauskas, Ruta , Flanagan, Meghan R., Dill, Ellen D., Joseph, Kathe-Ann P., Trifonov, Alexandr , Kim, Esther A. , Kantor, Olga, Barmettler, Gabi , Rosenberger, Laura H., Jordan, Sumanas W., Perez, Megan M. , Jimenez, Rachel B., Smart, Alicia , Walker, J C, Lautner, Meeghan A., Siegel, Emily L., Brabender, Danielle , Al-Hilli, Zahraa, Cassidy, Michael R., Weiss, Anna, McCaffrey, Rachel L., Lee, M Catherine, Kaoutzanis, Christodoulos, Nguyen, Khoa N., Son, Jennifer D., Williams, Austin D., Madrigrano, Andrea, McLaughlin, Sarah A., Stolley, Melinda, Cortina, Chandler S. , Flanagan, Meghan R. , Mukhtar, Rita A. , Kantor, Olga , Rezak, Kristen M. , Rosenberger, Laura H. , Jimenez, Rachel , Kopkash, Katherine A. , Hughes, Tasha M. , Walker, Jasmine C. , Lautner, Meeghan Ann, Siegel, Emily , Al‐Hilli, Zahraa , Cassidy, Michael Ryan , Weiss, Anna, McCaffrey, Rachel Louise , Kaoutzanis, Christodoulos , Son, Jennifer D. , Williams, Austin David , Petroll, Andrew E. , Stolley, Melinda R.

Mayo Clinic

JAMA Network Open | July 23, 2026 | Volume: 9 | Issue: 7 | Pages: e2624824

10.1001/jamanetworkopen.2026.24824 | PMID 42490110 Get It

Importance Limited granular data exist on breast cancer in transgender, nonbinary, and/or gender-diverse (TGD) individuals. Objective To describe patient demographic and tumor clinicopathological variables, clinically relevant risk factors, method of breast cancer detection, treatment characteristics, and locoregional outcomes and to estimate a 5-year breast cancer–specific survival (BCSS). Design, Setting, and Participants This cohort study obtained data on patients treated from 1990 to 2023 from 22 US academic medical centers using institutional databases, electronic medical records, and tumor registries. Included participants were TGD individuals 18 years or older with stage 0 to IV breast cancer. A comparative breast cancer cohort was selected from the 2016 to 2021 Surveillance, Epidemiology, and End Results Program (SEER) breast cancer dataset. Data were analyzed from January to October 2025. Exposure Breast cancer. Main Outcomes and Measures Estimated 5-year BCSS and locoregional recurrence rates. Wilcoxon rank sum and χ 2 tests were used to compare continuous and categorical variables. Kaplan-Meier analysis was used to estimate 5-year BCSS. Results A total of 112 TGD persons (median [IQR] age at diagnosis, 42.5 [36.5-51.0] years; 104 individuals [92.9%] were assigned female at birth) with breast cancer and 1 with bilateral disease were included in the analysis. Forty-three patients (38.4%) used gender-affirming hormone therapy before diagnosis. Among the entire cohort, 58 patients (51.8%) detected their own breast cancer, 68 (60.7%) had a familial breast cancer history, and 16 (14.3%) had a pathogenic germline variant. Tumors were predominantly hormone receptor positive (96 [85.7%]) and early stage (29 [25.7%] ductal carcinoma in situ [DCIS]; 51 [45.1%] stage I). The TGD cohort, compared with patients with breast cancer in the SEER dataset (N = 480 915), was younger (median [IQR] age, 42.5 [36.5-51.0] years vs 62.0 [52.0-72.0] years), had a higher proportion of persons assigned male at birth (8 [7.1%] vs 3522 [0.7%]), more often had progesterone receptor–positive disease (89 [79.5%] vs 335 491 [69.8%]), and presented with earlier-stage disease (eg, DCIS: 29 [25.9%] vs 79 604 [16.6%]). With a median (IQR) follow-up time for the TGD cohort of 38 (24-74) months, 5-year BCSS was favorable at 96.2% (95% CI, 85.3%-99.0%). Conclusions and Relevance This cohort study of TGD patients with breast cancer found that this population was young and often detected their own tumors via self-examination, suggesting opportunities to improve early detection through screening for individuals at elevated risk. Although short-term BCSS appeared favorable, prospective research is essential to define evidence-based guidelines and elucidate long-term outcomes.